Company: HROW
Filing Date: 2025-08-11
Form Type: 10-Q
Source: 0001641172-25-022980
Chunk: 47

Company: HARROW, INC.
Filing Date: 2025-08-11
Form: 10-Q
Item: Item 1
Chunk 47
---

    The
    ImprimisRx segment represents activities in the Company’s ophthalmology-focused pharmaceutical compounding business.

Segment
contribution for the segments represents net revenues less cost of sales, certain general and administrative expenses, selling and marketing
expenses, and research and development expenses. The Company does not evaluate the following items at the segment level:

    ●
    Selling,
    general and administrative expenses that result from shared infrastructure, including certain expenses associated with legal matters,
    public company costs (e.g. investor relations), Board of Directors and principal executive officers and other shared expenses.

    ●
    Operating expenses within selling, general and administrative expenses that result from the impact of corporate initiatives. Corporate initiatives primarily include integration, restructuring, acquisition and other shared costs.

    ●
    Other
    select revenues and operating expenses including research and development expenses, amortization, and asset sales and impairments,
    net as not all such information has been accounted for at the segment level, or such information has not been used by all segments.

Segment
net revenues, segment operating expenses and segment contribution information consisted of the following:

SCHEDULE
OF SEGMENT NET REVENUES

    Branded  
    Compounding  
    Consolidated  
    Branded  
    Compounding  
    Consolidated 

    Three Months Ended June 30, 2025  
    Three Months Ended June 30, 2024 

    Branded  
    Compounding  
    Consolidated  
    Branded  
    Compounding  
    Consolidated 
  
    Product sales, net 
    $42,189,000  
    $21,468,000  
    $63,657,000  
    $27,291,000  
    $21,580,000  
    $48,871,000 
  
    Other revenues 
     85,000  
     -  
     85,000  
     68,000  
     -  
     68,000 
  
    Total revenues 
     42,274,000  
     21,468,000  
     63,742,000  
     27,359,000  
     21,580,000  
     48,939,000 
  
    Cost of sales 
     8,734,000  
     7,496,000  
     16,230